GERALD A. BRUNK - 15 Jun 2024 Form 4 Insider Report for enGene Holdings Inc. (ENGN)

Role: Director
Signature: /s/ Alex J. Nichols, as attorney-in-fact for the Reporting Person
Issuer symbol: ENGN
Transactions as of: 15 Jun 2024
Net transactions value: $0
Form type: 4
Filing time: 18 Jun 2024, 16:04:17 UTC
Previous filing: 21 Feb 2024
Next filing: 16 Jun 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ENGN	Stock Option (Right to Buy)	Award	$0	+20,000		$0.000000	20,000	15 Jun 2024	Common Shares	20,000	$9.00	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders.
F2	These options are held of record by Mr. Brunk for the benefit of Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"). Mr. Brunk expressly disclaims beneficial ownership of these securities.

Content

This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was May 15, 2024; or (ii) the 2025 Annual Meeting of Shareholders.

These options are held of record by Mr. Brunk for the benefit of Lumira Ventures III, L.P. ("Lumira III"), Lumira Ventures III (International), L.P. ("Lumira III Int'l"), Lumira Ventures IV, L.P. ("Lumira IV"), Lumira Ventures IV (International), L.P. ("Lumira IV Int'l"), Merck Lumira Biosciences Fund, L.P. ("Merck-Lumira"), Merck Lumira Biosciences Fund (Quebec), L.P. ("Merck-Lumira B" and, together with Lumira III, Lumira III Int'l, Lumira IV, Lumira IV Int'l, and Merck-Lumira, the "Lumira Entities"). Mr. Brunk expressly disclaims beneficial ownership of these securities.